Introduction: At the 6th China International Import Expo, the world’s first Liverscan®️ Mobile series of portable liver elastography ultrasound diagnostic system independently developed by Eieling, a medical innovation company jointly incubated by the Hong Kong Polytechnic University and the Hong Kong Science Park, was unveiled in the Service and Trade Pavilion (8.2H). This is the first time that Eieling has appeared at the CIIE, showing the world its uniqueness and innovation as well as the achievements of Eieling ‘s first commercialization.
On the second day of the 6th CIIE, a highly anticipated technology new product launch conference was held as scheduled. The Liverscan®️ Mobile series products of Yiling Technology were officially launched under the attention of the audience, marking a new breakthrough in the field of medical technology.
The burden of liver disease in my country is heavy. The number of patients with chronic liver disease worldwide exceeds 1.33 billion, and the number of patients with chronic liver disease in China exceeds 400 million. The burden of chronic diseases accounts for more than 70% of the country’s total, and chronic non-communicable diseases account for 87% of deaths. Among them, the number of non-alcoholic fatty liver disease (NAFLD) patients worldwide is as high as 1 billion. The prevalence of NAFLD in the general population in China is 15% to 40%, which is higher than the global average prevalence (25.24%). In addition to increasing liver disease complications and liver disease deaths, NAFLD risk, and significantly increases the risk of cardiovascular disease. Common among patients with obesity and type 2 diabetes (T2DM), patients with NAFLD are twice as likely to die from cardiovascular disease as from liver disease. Therefore, we need to attach great importance to the prevention, control and management of non-alcoholic fatty liver disease (NAFLD).
Chronic liver diseases have different paths but the same end and the development process usually includes stages such as hepatitis, liver fibrosis, and cirrhosis. If hepatitis is not treated and controlled in time, it will lead to liver cell damage and necrosis; liver fibrosis is a fibrotic reaction in the process of liver tissue repair, and continued development will lead to liver structural changes and dysfunction; ultimately, cirrhosis is a late manifestation of chronic liver disease, with severe damage to liver tissue and functional decline. Liver hardness gradually increases with the progression of liver fibrosis. The histological stage of liver fibrosis S1 to S3 is asymptomatic and reversible. Seizing the golden window, early screening, early diagnosis and early treatment can effectively block the disease process and achieve reversal of liver fibrosis.
However, existing clinical diagnostic methods for liver fibrosis and steatosis have limitations. Liver biopsy is not feasible due to the high prevalence of steatosis in the general population. In addition to the associated costs and risks, liver biopsy is subject to sampling errors. The histological assessment of steatosis is qualitative and has considerable interobserver variability, which makes it less suitable for diagnosis and longitudinal follow-up. Given these shortcomings, accurate, reproducible, and noninvasive methods are urgently needed to assess steatosis.
The core patented technology of the Liverscan®️ Mobile series of portable liver elastography ultrasound diagnostic system, namely the combination of B-type ultrasound real-time image guide and TE, can effectively improve TE diagnostic performance. When doctors have doubts about the diagnosis results, they can combine B-type ultrasound liver parenchyma, vascular morphology, and other indicators in real-time to effectively reduce the missed diagnosis rate (cirrhosis with mild inflammation) and misdiagnosis rate (misdiagnosis of cirrhosis with severe inflammation).
Portable tablet workstation: 1 minute for the entire testing process, 4 hours of worry-free battery life; the probe card slot has both wireless charging and storage functions; the embedded flat-panel display and wireless folding operation panel take user habits into consideration; 1T hard disk storage space.
One-click detection with wireless composite probe: The elastic detection probe integrates the B-type ultrasound real-time image guide function, and there is no need to switch probes during the detection process; a single probe can cover people with overweight and central obesity; one trigger can simultaneously obtain liver tissue hardness (kPa), ultrasonic fatty degeneration parameters (dB/m), statistical values and detection success rate.
Jiang Tianyu, senior product manager of Eieling Technology, explained in detail the functions and advantages of the Liverscan®️ Mobile series products to the guests present. She deeply elaborated on the medical diagnosis, treatment, and application of this product in three major scenarios: “early screening of major diseases (diabetes, liver disease)”, “construction of regional chronic disease (fatty liver) management network”, and “health cabin-new model of health service”. The important role in the rehabilitation process and how it uses scientific and technological means to make medical services more convenient and accurate, empower government medical insurance policies and medical insurance system reforms, significantly reduce the workload of doctors, effectively increase the rate of grassroots medical treatment, and assist Establish special outpatient clinics to increase income, reduce the death and disability rate caused by chronic diseases, and improve the health level of non-standard groups (chronic diseases, sub-health, and past medical conditions) to meet the diverse health needs of the public.
Before the official launch of the product, Jia Xiaojia, CEO of Eieling, delivered an opening speech for the conference. He warmly welcomed all the guests and expressed high hopes for the future of the Liverscan®️ Mobile series. He said: ” Eieling Technology has always been committed to the innovation and development of medical technology. We hope to achieve the extension of high-end technology to the grassroots level and solve practical clinical problems through innovative products.”
The conference was also honored to invite several important guests to give speeches. They are Professor Wang Jiada, Director of Knowledge Transfer and Innovation Office of Hong Kong Polytechnic University, Zhang Shihui, Director of Service Industry Development of Hong Kong Trade Development Council, Li Wei, Director of Science and Technology Innovation Bureau of Suzhou High-tech Zone, Professor Qi Xiaolong, Assistant Dean of Zhongda Hospital Affiliated to Southeast University, Wu Xinfen, Chairman of Chongqing Huiren Health Management Co., Ltd., and Wang Zhigang, General Manager of Shanghai Peking University Science Park. All the guests congratulated and looked forward to the launch of Liverscan®️ Mobile series products from their respective professional perspectives, and praised the R&D spirit of Eieling Technology.
In addition to the encouragement and support from all the guests, this conference also received active participation from many medical institutions and agents from all over the country. Their presence not only highlights the wide influence of the Liverscan ®️ Mobile series of products, but also further proves the leading position of Eieling Technology in the field of medical technology.
The launch of the Liverscan®️ Mobile series of products has undoubtedly injected new vitality into the field of medical technology. We look forward to this series of products making a substantial contribution to the medical and health care of the grassroots in the future. At the same time, we also look forward to Eieling Technology continuing to move forward on the road of technological innovation, developing more excellent medical technology products, serving patients around the world, and promoting the progress of medical and health care.